Under the five-year deal, Clovis will utilize EndolucinBeta for the clinical development of its FAP-2286 fibroblast activation protein (FAP)-targeted radionuclide therapy candidate, according to the companies. FAP-2286 consists of a targeting peptide that binds to FAP and a site that can be used to attach radioisotopes, such as lutetium-177 for therapeutic use, or gallium-68 for imaging use, the companies said.
FAP-2286 is currently being investigated in a phase I/II study in patients with advanced solid tumors. Additional terms of the agreement were not disclosed.
Copyright © 2021 AuntMinnieEurope.com